Penn Medicine Abramson Cancer Center


 

2021 Penn Medicine Update on FLT3i in R/R AML: Gilteritinib Mono and in Combination With Venetoclax, Newer Agents in Frontline Intensive Therapy and Post-transplant Maintenance

123 views
March 2, 2021
Comments 0
Login to view comments. Click here to Login